What does biopharma systems — operating income (loss) mean?

This metric represents the total operating profit or loss generated by the BioPharma Systems segment after accounting for all operating costs, including COGS, SG&A, R&D, and other operating items. It is the primary measure of the segment's core operational profitability.

Becton, Dickinson and Company BDX BioPharma Systems — Operating Income (Loss)

Other segment segments

Medical

$4.14B+15.5%

Interventional

$579M+2.5%

Medical Essentials

$574M-7.0%

Connected Care

$347M-1.7%

Similar metrics at other companies

ANABBiopharma Company — Operating Income

-$52.81M-3.0%

TMOLaboratory Products and Biopharma Services — Operating Income (Loss)

$778M+6.4%

LHBiopharma Laboratory Services — Operating Income

$120.7M+12.9%

JAN

JANBiotech — Operating Income

-$177K+67.2%

BLCOPharmaceuticals — Operating Income (Loss)

$66M+500%

ANABBiopharma Company — Net Income Loss

-$50.48M-7.0%

Other financials

Income statement

See full

Revenue$4.7B+5.2%

Gross profit$2.2B+15.7%

Operating income$93.0M-75.7%

Net income-$311.0M-201%

EPS (diluted)-$1.11-204%

Balance sheet

See full

Cash & equivalents$1.0B+49.0%

Total debt$14.7B-16.8%

Total equity$24.1B-4.4%

Total assets$50.8B-6.7%

Cash flow

See full

Operating cash flow$671.0M—

CapEx$125.0M+9.6%

Free cash flow$546.0M—

Valuation

See full

Market cap$42.96B-12.6%

Enterprise value$56.65B-14.0%

P/E37.8×+6.7×

P/S2×-0.4×

Profitability

See full

Gross margin46.8%+2.5pp

Operating margin10.4%+0.1pp

Net margin5.3%-2.1pp

FCF margin16.4%—

Returns & leverage

See full

Return on equity4.6%-1.3pp

Debt / equity0.6×-0.1×

Current ratio0.9×-0.2×

Where this comes from

Reported directly by Becton, Dickinson and Company in its filing.

Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.

The official record: Becton, Dickinson and Company’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Becton, Dickinson and Company's biopharma systems — operating income (loss).

Connect your AI assistant and compare segments, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Becton, Dickinson and Company's biopharma systems — operating income (loss)?: Becton, Dickinson and Company (BDX) reported biopharma systems — operating income (loss) of $225M in Q1 2026.
What does biopharma systems — operating income (loss) mean?: This metric represents the total operating profit or loss generated by the BioPharma Systems segment after accounting for all operating costs, including COGS, SG&A, R&D, and other operating items. It is the primary measure of the segment's core operational profitability.